Key Takeaways:
- Microsoft and Bristol Myers Squibb have partnered to improve lung cancer detection using AI-powered radiology tools
- The partnership aims to identify non-small cell lung cancer (NSCLC) more quickly across U.S. hospitals
- The effort will focus on detection in medically underserved communities, including rural hospitals and community clinics
- The partnership has the potential to expand the use of BMS’s Opdivo drug for NSCLC
- The collaboration will utilize Microsoft’s Precision Imaging Network, which is used by over 80% of hospitals in the U.S.
Introduction to the Partnership
Microsoft and Bristol Myers Squibb have signed a new agreement aimed at improving the detection of lung cancer cases in the United States. As stated in the press release, "Lung cancer remains a major medical issue in the U.S., with about 125,000 deaths and 227,000 new cases reported each year, and higher mortality rates in rural areas." The partnership will utilize Microsoft’s suite of artificial-intelligence-powered radiology tools to help detect non-small cell lung cancer (NSCLC) more quickly across U.S. hospitals. According to Peter Durlach, corporate vice president and chief strategy officer for Microsoft Health and Life Sciences, "With Microsoft’s AI-powered radiology technology platform widely deployed within healthcare delivery organizations across the country and operating behind the scenes, clinicians can more easily identify patients who may be showing early signs of cancer—often before they are aware of any symptoms—and help guide them into the appropriate care pathway sooner."
The Technology Behind the Partnership
The partnership will leverage Microsoft’s Precision Imaging Network, which is designed to share medical imaging and access third-party imaging AI. This network is already used by more than 80% of hospitals in the U.S., making it a valuable tool for the partnership. As the tech company said in a Jan. 20 release, the network will enable BMS to tap into AI tools that automatically analyze X-ray and CT images to help identify lung disease, including hard-to-detect nodules. This technology has the potential to revolutionize the way lung cancer is detected, particularly in medically underserved communities. As Durlach noted, the AI-powered radiology technology platform will "help guide them into the appropriate care pathway sooner," which could lead to better patient outcomes.
The Impact on Medically Underserved Communities
The partnership will focus on detection in medically underserved communities, including rural hospitals and community clinics. This is a critical aspect of the agreement, as lung cancer mortality rates are higher in rural areas. By utilizing Microsoft’s AI-powered radiology tools, the partnership aims to reduce these disparities and improve health outcomes for patients in these communities. As the press release highlighted, "Beyond speeding potential NSCLC diagnoses, the effort will also focus on detection in medically underserved communities, including rural hospitals and community clinics." This effort has the potential to make a significant impact on the lives of patients in these communities, who often face barriers to accessing quality healthcare.
The Potential for Expanded Treatment Options
The partnership also has the potential to expand the use of BMS’s Opdivo drug for NSCLC. As BMS markets Opdivo for NSCLC in the U.S. and several other cancer indications, earlier diagnosis could lead to increased use of the drug. This could be a significant development for patients with NSCLC, who often face limited treatment options. As Durlach stated, the partnership will enable clinicians to "more easily identify patients who may be showing early signs of cancer—often before they are aware of any symptoms—and help guide them into the appropriate care pathway sooner." This could lead to more patients receiving timely and effective treatment, which could improve health outcomes and save lives.
Conclusion
In conclusion, the partnership between Microsoft and Bristol Myers Squibb has the potential to revolutionize the way lung cancer is detected and treated in the United States. By leveraging Microsoft’s AI-powered radiology tools and BMS’s expertise in cancer treatment, the partnership aims to improve health outcomes for patients with NSCLC. As the press release noted, "Lung cancer remains a major medical issue in the U.S.," but this partnership offers hope for a better future for patients with this disease. With its focus on medically underserved communities and its potential to expand treatment options, this partnership is an important step forward in the fight against lung cancer.
https://www.fiercebiotech.com/medtech/bristol-myers-squibb-signs-microsofts-ai-detection-network-speedy-lung-cancer-diagnosis